Organogenesis Holdings Inc (ORGO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $105.15M
Last updated: Nov 17, 2026 at 11:06 AM ET
Organogenesis Holdings Inc (ORGO) Financials: Revenue, Profit and Cash Flow
Organogenesis Holdings reported revenue of $564.17M for the fiscal year ended Dec 31, 2025, up 17.0% from the year before. That year, net income was $37.03M with a net margin of 6.6%, operating cash flow was -$10.31M and free cash flow was -$24.46M. The quarter ended Sep 30, 2026 had revenue of $45.46M and net income of -$29.63M.
Revenue and Margins
The operating margin was 7.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $138.73M, a compound annual rate of 16.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $564.17M | +17.0% | 75.6% | 7.9% | 6.6% |
| Dec 2024 | $482.04M | +11.3% | 76.0% | -0.3% | 0.2% |
| Dec 2023 | $433.14M | -3.9% | 75.4% | 2.9% | 1.1% |
| Dec 2022 | $450.89M | -3.5% | 76.7% | 4.9% | 3.4% |
| Dec 2021 | $467.36M | +38.2% | 75.6% | 15.5% | 20.2% |
| Dec 2020 | $338.30M | +29.6% | 74.2% | 7.9% | 5.1% |
| Dec 2019 | $260.98M | +34.9% | 70.9% | -11.4% | -14.8% |
| Dec 2018 | $193.45M | -2.5% | 64.4% | -26.7% | -33.5% |
| Dec 2017 | $198.51M | +43.1% | 69.2% | -2.8% | -3.8% |
| Dec 2016 | $138.73M | N/A | 65.3% | -6.3% | -10.6% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 4200.8% from the year before. In the quarter ended Sep 2026, the company posted a net loss after a profit in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $564.17M | $482.04M | $433.14M | $450.89M | $467.36M | $338.30M | $260.98M | $193.45M | $198.51M | $138.73M |
| Cost of revenue | $137.52M | $115.74M | $106.48M | $105.02M | $114.20M | $87.32M | $75.95M | $68.81M | $61.22M | $48.20M |
| Gross profit | $426.65M | $366.30M | $326.66M | $345.87M | $353.16M | $250.98M | $185.03M | $124.64M | $137.29M | $90.53M |
| Research and development | $44.54M | $50.27M | $44.38M | $39.76M | $30.74M | $20.09M | $14.80M | $10.74M | $9.06M | $6.28M |
| Operating income | $44.69M | -$1.28M | $12.53M | $22.30M | $72.22M | $26.70M | -$29.85M | -$51.56M | -$5.49M | -$8.78M |
| Net income | $37.03M | $861.00K | $4.95M | $15.53M | $94.20M | $17.23M | -$38.71M | -$64.83M | -$7.53M | -$14.77M |
| EBITDA | $63.28M | $15.76M | $27.95M | $40.32M | $88.88M | $37.23M | -$17.88M | -$44.88M | -$912.00K | -$1.91M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45.46M | $43.76M | $37.23M | $225.61M | $150.86M | $101.00M | $86.69M | $126.66M | $115.18M | $130.23M | $109.98M | $99.65M |
| Gross profit | $23.56M | $20.08M | $11.46M | $175.69M | $114.61M | $73.38M | $62.97M | $95.61M | $88.38M | $101.04M | $81.28M | $71.88M |
| Operating income | -$29.49M | -$50.99M | -$68.89M | $63.29M | $20.73M | -$12.58M | -$26.75M | $10.22M | $6.24M | -$13.89M | -$3.85M | -$1.27M |
| Net income | -$29.63M | -$96.27M | -$53.16M | $43.70M | $21.57M | -$9.39M | -$18.84M | $7.67M | $12.33M | -$17.04M | -$2.10M | -$569.00K |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded total debt of $4.95M by $88.73M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $598.73M | $497.89M | $460.02M | $449.36M | $443.26M | $290.22M | $220.69M | $163.68M | $148.72M | $311.44M |
| Current assets | $362.19M | $285.94M | $225.04M | $222.61M | $226.98M | $174.34M | $125.60M | $71.13M | $49.74M | $1.44M |
| Cash and equivalents | $93.68M | $135.57M | $103.84M | $102.48M | $113.93M | $84.39M | $60.17M | $21.29M | $2.31M | $1.04M |
| Total liabilities | $164.81M | $112.57M | $181.36M | $183.69M | $201.92M | $148.41M | $165.10M | $116.64M | $157.28M | $11.33M |
| Short-term debt | $4.95M | $0 | $18.63M | $4.54M | $14.44M | $16.67M | $3.06M | $9.78M | $10.37M | $0 |
| Long-term debt | $0 | $0 | $60.74M | $66.23M | $70.77M | $53.04M | $83.12M | $39.06M | $84.58M | $73.39M |
| Shareholder equity | $300.13M | $262.90M | $278.66M | $265.67M | $241.34M | $141.81M | $55.58M | $47.04M | -$15.32M | $5.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $368.90M | $406.45M | $519.99M | $598.73M | $509.83M | $461.13M | $467.39M | $497.89M | $446.30M | $443.16M | $458.48M | $460.02M |
| Total liabilities | $106.16M | $118.31M | $138.65M | $164.81M | $123.85M | $99.91M | $99.33M | $112.57M | $167.75M | $179.66M | $180.45M | $181.36M |
| Cash and equivalents | $21.33M | $46.10M | $91.38M | $93.68M | $63.74M | $73.08M | $109.97M | $135.57M | $94.34M | $89.90M | $88.63M | $104.34M |
| Shareholder equity | $119.74M | $148.27M | $244.56M | $433.92M | $255.13M | $233.24M | $242.90M | $385.32M | $278.55M | $263.50M | $278.03M | $278.66M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.31M | $14.21M | $30.92M | $24.86M | $61.98M | $5.47M | -$33.53M | -$60.63M | -$3.49M | -$4.87M |
| Capital expenditures | $14.15M | $10.03M | $24.36M | $33.90M | $31.22M | $17.68M | $5.98M | $1.86M | $2.43M | $1.36M |
| Free cash flow | -$24.46M | $4.18M | $6.55M | -$9.04M | $30.76M | -$12.21M | -$39.51M | -$62.49M | -$5.92M | -$6.23M |
| Dividends paid | $11.37M | $1.80M | N/A | $648.00K | $1.46M | N/A | $57.90M | N/A | N/A | $5.20M |
| Share repurchases | $0 | $25.48M | $0 | $0 | $0 | $5.66M | $2.97M | $270.00K | N/A | N/A |
| Investing cash flow | -$14.15M | -$10.03M | -$24.36M | -$33.90M | -$31.22M | -$23.50M | -$6.23M | -$1.86M | -$14.87M | -$1.25M |
| Financing cash flow | -$17.36M | $27.64M | -$5.50M | -$2.20M | -$1.04M | $42.47M | $78.73M | $81.54M | $18.87M | $6.78M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.59M | -$31.65M | $21.13M | $39.42M | $3.08M | -$32.87M | -$19.93M | $10.94M | $8.70M | $4.74M | -$10.16M | $10.61M |
| Capital expenditures | $1.47M | $1.10M | $3.15M | $4.65M | $2.23M | $3.64M | $3.63M | $3.36M | $2.57M | $1.88M | $2.22M | $3.32M |
| Free cash flow | -$20.06M | -$32.75M | $17.98M | $34.77M | $844.00K | -$36.51M | -$23.56M | $7.58M | $6.13M | $2.86M | -$12.38M | $7.29M |
Frequently Asked Questions About ORGO
What is Organogenesis Holdings' annual revenue?
Organogenesis Holdings reported revenue of $564.17M for the fiscal year ended Dec 31, 2025.
How fast is Organogenesis Holdings' revenue growing?
Revenue was up 17.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 7.8%.
Is Organogenesis Holdings profitable?
Yes. Organogenesis Holdings reported net income of $37.03M for the fiscal year ended Dec 31, 2025, with a net margin of 6.6%.
How much free cash flow does ORGO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$10.31M minus capital expenditures of $14.15M produced free cash flow of -$24.46M.
How much debt does Organogenesis Holdings have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $4.95M and cash and equivalents of $93.68M.
ORGO pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts